RxDoctor Payments Data

Garfield Johnson, MD

Otolaryngology · Houston, TXNPI 1104814573

Payments from drug & device makers

$9,679in general payments, 2019–2025

Across 120 payments — averaging $80.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acelrx Pharmaceuticals, Inc.$2K
  • Medtronic$2K
  • Acclarent, Inc$2K
  • Integra Lifesciences Corporation$903
  • Stryker$734
  • Aerin Medical Inc.$445
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$2,25023%
  • Travel & lodging$1,27413%
  • Food & beverage$6,15564%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,679 in reported general payments places this provider in the 85th percentile of 729 otolaryngology providers in Texas.

See all otolaryngology providers in Texas

Medicare billing

Part B allowed, 2024
$253,137
Medicare patients
621
Services billed
3,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide375$9,686
Arnuity ElliptaFluticasone Furoate29$6,468
Fluticasone Propionate350$5,324
Omeprazole123$3,480
Azelastine Hcl136$3,218
Epinephrine19$2,946
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth18$1,919
Cefdinir103$1,709
Prednisolone Acetate54$1,573
Montelukast Sodium116$1,058
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip69$1,029
Ofloxacin47$779
Desloratadine14$494
Prednisone237$429
Azithromycin36$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$214$6,46829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 729 otolaryngology providers in Texas.

Other otolaryngology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →